Portal de Periódicos da CAPES

The Development of Brequinar as an Immunosuppressive Drug for Transplantation

1993; Wiley; Volume: 136; Issue: 1 Linguagem: Inglês

10.1111/j.1600-065x.1993.tb00654.x

1600-065X

L Makowka, Linda Sher, Donald V. Cramer,

Parasitic Infections and Diagnostics

Immunological ReviewsVolume 136, Issue 1 p. 51-70 The Development of Brequinar as an Immunosuppressive Drug for Transplantation Leonard Makowka, Corresponding Author Leonard Makowka Transplantation Biology Research Laboratory, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.Dr. Leonard Makowka, Chairman, Department of Surgery, 610 Schuman Building, Cedars-Sinai Medical Center, Los Angeles, CA 90048, U.S.A.Search for more papers by this authorLinda S. Sher, Linda S. Sher Transplantation Biology Research Laboratory, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.Search for more papers by this authorDonald V. Cramer, Donald V. Cramer Transplantation Biology Research Laboratory, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.Search for more papers by this author Leonard Makowka, Corresponding Author Leonard Makowka Transplantation Biology Research Laboratory, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.Dr. Leonard Makowka, Chairman, Department of Surgery, 610 Schuman Building, Cedars-Sinai Medical Center, Los Angeles, CA 90048, U.S.A.Search for more papers by this authorLinda S. Sher, Linda S. Sher Transplantation Biology Research Laboratory, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.Search for more papers by this authorDonald V. Cramer, Donald V. Cramer Transplantation Biology Research Laboratory, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.Search for more papers by this author First published: December 1993 https://doi.org/10.1111/j.1600-065X.1993.tb00654.xCitations: 45AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Arteaga, C. L., Brown, T. D., Kuhn, J. G., Shen, H. L., O'Rourke. T. J., Beougher, K., Brentzel, H. J., Von Hoff, D. D. & Weiss, G. R. (1989) Phase I clinical and pharmacokinetic trial of Brequinar sodium (DUP 785; NSC 368390). Cancer Research 49, 4648. Barnes, T. B., Campbell, P., Zajac, I. & Gayda, D. (1993) Toxicological and pharmacokinetic effects following coadministration of brequinar sodium and cyclosporin A to spraguedawley rats. Transplant. Proc. (in press). Chen, S-F., Ruben, R. & Dexter, D. (1986) Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-niethyl-4-quinolinecarboxylic acid sodium salt (NSC 368390): Inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Research 46, 5014. Collins, B. H., Areford, M. L., Fabian, M. A., Jaffee, B. D. & Bollinger, R. R. (1993) Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. Transplant. Proc. 25 Suppl. 2, 37. Cosenza, C. A., Cramer, D. V. Eiras-Hreha, G., Cajulis, E., Wang, H. K. &. Makowka, L. (1993a) The synergism of brequinar sodium and cyclosporine when used in combination to prevent cardiac allograft rejection in the rat. Transplantation 56, 667. Cosenza, C., Tuso, P. J., Chapman, F. A., Middleton, Y. D., Cramer, D. V, Wu, G. D. & Makowka, L. (1993) Prolonged xenograft survival following combination therapy with Brequinar sodium and cyclosporine. Transplant. Proc. 25 Suppl 2, 59. Cosenza, C. A., Tuso, P. J., Chapman, F. A., Middleton, Y. D., Cramer, D. V, Wu, G. D. & Makowka, L. (1993b) Prolonged xenograft survival following combination therapy with Brequinar sodium and cyclosporine. Transplant. Proc. 25 Suppl. 2, 59. Cramer, D. V., Chapman, F. A., Jaffee, B. D., Jones, E. A., Knoop, M., Hreha-Eiras, G. & Makowka, L. (1992a) The effect of a new immunosuppressive drug, Brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 53, 303. Cramer, D. V., Chapman, F. A., Jaffee, B. D., Zajac, I., Hreha-Eiras, G., Yasunaga, C., Wu, G.-D. & Makowka, L. (1992b) The prolongation of concordant hamster-to-rat cardiac xenografts by Brequinar sodium. Transplantation 54, 403. Cramer, D. V., Knoop, M., Chapman, F. A., Wu, G. D., Jaffee, B. D. & Makowka, L. (1992c) Prevention of liver allograft rejection in rats by a short course of therapy with Brequinar sodium. Transplantation 54, 752. Eiras-Hreha, G. (1993) Brequinar sodium: Monitoring immunosuppressive activity. Transplant. Proc. 25 Suppl. 2, 32. Hancock, W. W., DiStefano, R., Braun, R., Schweizer, R. T., Tilney, N. L. & Kupiec-Weglinski, J. W. (1990) Cyclosporine and anti-interleukin 2 receptor monoclonal anti-body therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms. Transplantation 49, 416. Jaffee, B. D., Jones, E. A., Loveless, S. E. & Chen, S. F. (1993a) The unique immunosuppressive activity of Brequinar sodium. Transplant. Proc. 25 Suppl 2, 19. Jaffee, B. D., Jones, E. A., Zajac, I., Magolda, R. L., Cramer, D. V. & Makowka, L. (1993b) Effects of Brequinar sodium on cynomolgus monkeys: Immunosuppression and pharmacokinetics. Transplant. Proc. 25, 710. Kahan, B. D. (1989) Cyclosporine. N. Engl. J. Med. 321, 1725. Loveless, S. E. & Neubauer, R. H. (1986) Antimetastatic activity of DUP-785: a novel anticancer agent. Proc. Am. Assoc. Cancer Res. 27, 276. Makowka, L., Chapman, F. A. & Cramer, D. V. (1993a) The historical development of Brequinar sodium as a new immunosuppressive drug for transplantation. Transplant. Proc. 25 Suppl 2, 2. Makowka, L. & Cramer, D. V. (1992) Brequinar sodium: A new immunosuppressive drug for transplantation. Transplantation Science 2, 50. Makowka, L. & Cramer, D. V. (1993) The pathogenesis of the xenograft reaction. In: Advances in Transplantation. B. Hackel and J. Aubuchon (eds). Amer. Assoc. Blood Banks. Bethesda. pp. 93–112, 1993. Makowka, L., Tixier, D., Chaux, A., Hill, D., O'Neill, P., Eiras-Hreha, G., Wu, G. D, Hough, K., Cajulis, E., Zajac, I., Jaffee, B. D., Chapman, F. A. & Cramer, D. V. (1993b) The use of Brequinar sodium for preventing cardiac allograft rejection in primates. Transplant. Proc. 25 Suppl 2, 48. Maroun, J., Ruckdeschel, J., Natale, R., Morgan, R., Dallaire, B., Sisk, R. & Gyves, J. (1993) Multicenter phase II study of Brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol 32, 64. Murase, N., Starzl, T. E., Demetris, A. J., Valdivia, L., Tanabe, M., Cramer, D. V. & Makowka, L. (1993) Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation 55, 701. Noe, D. A., Rowinsky, E. K., Shen, H-S. L., Clarke, B. V., Grochow, L. B., McGuire, W. B., Hantel, A., Adams, D. B., Adeloff, M. D. Ettinger, D. S. & Donehower, R. C. (1990) Phase I and Pharmacokinetic Study of Brequinar sodium (NSC 368390). Cancer Research 50, 4595. Peters, G. J., Laurensse, E., Leyva, A. & Pinedo, H. M. (1987) A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography. Analyt. Biochem. 161, 32. Peters, G. J., Nadal, J. C., Laurensse, E. J., De Kant, E. & Pinedo, H. M. (1990a) Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer. Biochemical Pharmacology 39, 135. Peters, G. J., Schwartsmann, G., Nadal, J. C., Laurensse, E., van Groeningen, C. J., Vander Vijgh, W. J. F & Pinedo, H. M. (1990b) In Vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by Brequinar sodium (DUP-785;NSC 368390) in mice and patients. Cancer Res. 50, 4644. Schwartsmann, G., Bork, E., Vermorken, J. B., Nieboer, C., Dodion, P., Ten Bokkel Huinink, W. W., Seldenrijk, C. A., Armand, J. P. & Pinedo, H. M. (1989) Muccocutaneous side effects of Brequinar sodium: A new inhibitor of pyrimidine de novo biosynthesis. Cancer 63, 243. Schwartsmann, G., Dodion, P., Vermorken, J. B., Ten Bokkel Huinink, W. W., Joggi, G., Winograd, B., Gall, H., Simonetti, G., van der Vijgh, W. J., van Hennik, M. B., Crespeigne, N. & Pinedo, H. M. (1990) Phase I study with Brequinar Sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother Pharmacol 25, 345. Shen, H-S, Chen, S-F., Behrens, D., Whitney, C., Dexter, D. & Forbes, M. (1988) Distribution of the novel anticancer drug candidate Brequinar Sodium (Du785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts. Cancer Chemother Pharmacol 22, 183. Simon, P. Townsend, R. M., Harris, R. R., Jones, E. A. & Jaffee, B. D. (1993) Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools and consequent inhibition of immune functions in vitro. Transplant. Proc. 25 Suppl 2, 77. Stepkowski, S. M. & Kahan, B. D. (1993) The synergistic activity of the triple combination: cyclosporine, rapamycin, and Brequinar. Transplant. Proc. 25 Suppl 2, 29. Thomson, A. W. (1990) FK 506; profile of an important new immunosuppressant. Transplantation Review 4, 1. Urba, S., Doroshow, J., Cripps, C., Robert, F., Velez-Garcia, E., Dallaire, B., Adams, D., Carlson, R., Grillo-Lopez, A. & Gyves, J. (1992) Multicenter phase II trial of Brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck. Cancer Chemother Pharmacol 31, 167. Vathsala, A., Goto, S., Yoshimura, N., Stepkowski, S. M., Chou, T-C. & Kahan, B. D. (1991) The immunosuppressive antagonism of low doses of FK 506 and cyclosporine. Transplantation 52, 121. Yasunaga, C., Cramer, D. Y. Chapman, F. A., Wang, H. K., Barnett, M., Wu, G.-D. & Makowka, L. (1993a) The prevention of accelerated cardiac allograft rejection in sensitized recipients following treatment with Brequinar sodium. Transplantation (in press). Yasunaga, C., Cramer, D. V. Cosenza, C. A., Tuso, P. J., Chapman, F. A., Barnett, M., Wu, G. D., Putnam, B. A. & Makowka, L. (1993b) The effect of Brequinar sodium on in vivo antibody production. Transplant. Proc. 25 Suppl 2, 40. Citing Literature Volume136, Issue1December 1993Pages 51-70 ReferencesRelatedInformation